Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579730 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 188
- Enrollment target
NCT05579730 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 188 participants.
The verdict
NCT05579730, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 188 participants
- Enrollment target
Study Summary
To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
Interventions
- DRUG Vehicle
- DRUG Brimonidine Tartrate 0.025%
- DRUG Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%
- DRUG Ketotifen Fumarate 0.035%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2023-07-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05579730
The ClinicalTrials.gov registry entry for NCT05579730 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vehicle is the first listed.
NCT05579730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05579730 about?
NCT05579730 is a clinical study titled "Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis". To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
What is the current status of trial NCT05579730?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 188 participants. The study started on 2022-10-12. Estimated completion is 2023-07-22.
What interventions are being tested in trial NCT05579730?
The interventions under investigation include: Vehicle (DRUG), Brimonidine Tartrate 0.025% (DRUG), Brimonidine tartrate 0.025%/ketotifen fumarate 0.035% (DRUG), Ketotifen Fumarate 0.035% (DRUG).
Who is sponsoring clinical trial NCT05579730?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.